Pyridazinones and methods of use thereof

A compound represented by Formula (I) or (III), or a tautomer or a pharmaceutically acceptable salt thereof;

• wherein
• R1 and R3 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, halogen, —OH, —CN, -cycloalkyl, —O-alkyl, —O-cycloalkyl, —O-aryl, -aryl-O-aryl, —CF3, —C(H)F2, alkylene-CF3, alkylene-C(H)F2, —SO2-alkyl, and —O-alkylene-O-alkyl;
• R2 is a -heterocyclyl-L-R4 selected from the group consisting of:
• wherein L is methylene or —C(R5)(R6)-, and R4 is aryl, alkylene-aryl, alkylene-heteroaryl, heteroaryl, or heterocyclyl;
• wherein R4 is an oxazole ring, pyrazole ring, pyridine ring, pyrazine ring, pyridazine ring, or pyrimidine ring, wherein R4 is substituted with at least one substituent independently selected from the group consisting of alkyl, cycloalkyl, halogen, —CN, —CF3, and -C(H)F2;
• and
• (C) a -heterocyclyl-L-R4 wherein the heterocyclyl is selected from
• wherein R7 is H, alkyl, —O-aryl, —O-alkyl, or cycloalkyl;
• L is methylene or —C(R5)(R6)-;
• and R4 is aryl, alkylene-aryl, alkylene-heteroaryl, heteroaryl, or heterocyclyl;
• R5 is independently H or alkyl;
• and
• R6 is selected from the group consisting of alkyl and -CF3.